One sentence summary: Amino acid substitutions of CaErg11p are prevalent and the substitution T123I confers resistance to azole, and has a synergistic effect on voriconazole resistance with the substitution Y132H.
INTRODUCTION
Fungal infections have increased markedly over the past several years, mainly because of the rapidly increasing number of immunocompromised patients due to cancer chemotherapy and radiotherapy, HIV-AIDS and organ transplants (Brown, Denning and Levitz 2012) . Candida albicans is the most prevalent etiology of fungal infections and contributes to a wide range of clinical infections, ranging from mucosal infections to systemic fungal infections (Klingspor et al. 2015) . The azole antifungal class, particularly fluconazole, has been widely used in the treatment of C. albicans infections over the past 30 years because of its efficacy and low rate of side effects. However, the widespread uses of azole drugs and repeated treatment courses have rendered the problem of azole resistance more serious, and it has become a difficult problem in the treatment of fungal infections (Sanguinetti, Posteraro and Lass-Flörl 2015) .
Studies on the mechanisms of azole resistance have made a significant contribution to the design of newer antifungals and the development of guidelines for clinical treatment. To date, mechanisms related to azole resistance have been studied extensively. For example, azole resistance was found to be attributed to upregulation of drug efflux, including the ATP binding cassette family and the major facilitator superfamily (Prasad and Rawal 2014; Lo et al. 2015; Rawal et al. 2016) . Moreover, a specific mutation in the ERG11 gene that causes the structural alteration of the azole target enzyme, lanosterol 14α-demethylase (CaErg11p), is the most common mechanism underlying azole resistance (Alvarez-Rueda et al. 2011; Flowers et al. 2014) . Interestingly, not all amino acid substitutions of Erg11p are correlated with azole resistance. Though three stretches of amino acid residues (105-165, 266-287 and 405-488) of CaErg11p have been reported to be hot spots (Marichal et al. 1999) , only a few amino acid substitutions have been confirmed to confer resistance to azole by biological evidence (Xiang et al. 2013) .
In order to identify novel ERG11 mutations associated with azole resistance, we amplified and sequenced the ERG11 gene from 45 fluconazole-resistant and 10 susceptible clinical isolates. These sequencing results yielded a new homozygous substitution, T123I, which was only present in 27 fluconazoleresistant isolates harboring another homozygous substitution Y132H. A previous study confirmed that the substitution Y132H contributes to azole resistance (Xiang et al. 2013) . Although the threonine residue 123 is located in the first hot spot of CaErg11p, the biological significance of this mutation to azole resistance, especially its synergy with the substitution Y132H, remains largely unknown.
In this study, we introduced the single C368T (T123I) mutation, which means that the 368th base of the ERG11 gene is changed from C to T, leading to the conversion of the 123rd amino acid from T to I, T394C (Y132H) mutation and double mutations into the wild-type ERG11 gene of SC5314 strain by the site-directed mutagenesis assays and expressed the different versions of C. albicans ERG11 gene into the budding yeast S. cerevisiae. The contribution of this newly identified homozygous substitution T123I to azole resistance and its synergistic effect with the substitution Y132H were assessed in vitro.
MATERIALS AND METHODS

Strains and media
A total of 55 clinical isolates were collected from the Obstetrics and Gynecology Hospital of Fudan University, the Shanghai First Maternity and Infant Hospital and the International Peace Maternity and Child Health Hospital (Shanghai, China) between August 2015 and March 2016. All isolates were cultured on CHROMagar Candida (CHROMagar, Paris, France) for green colonies, and finally identified by API 20C AUX (Biomerieux, Lyon, France). In addition, the ATCC 90028 strain and ATCC 22019 strain were served as controls for antifungal susceptibility testing. Saccharomyces cerevisiae strain INVSc-1 (MATa his3 1/his3 1 leu2/leu2trp1-289/trp-289ura3-52/ura3-52, His-, Leu-, Trp-, Ura-) and plasmid pYES2/CT were provided by Professor Mingjie Xiang (Ruijin Hospital Luwan Branch, Shanghai Jiao Tong University School of Medicine, China). The Escherichia coli strain DH5α and Luria-Bertani (LB) broth or LB agar plates supplemented with 100 μg/ml ampicillin (Sigma, American) were used for transformation and plasmid DNA preparation. SD-URA3-2% glucose media (yeast synthetic dropout media without uracil containing 2% glucose) were used to screen transformants. SD/Gal/Raf/-Ura media (yeast synthetic dropout media without uracil containing 2% galactose and 2% raffinose) were used to induce heterologous expression of CaErg11p.
ERG11 gene amplification and sequencing
We extracted the clinical isolates of genomic DNA that had served as templates for amplification of the ERG11 gene according to the instructions provided in the E.Z.N.ATM Yeast DNA Kit (Yeasen, Shanghai, China). Two pairs of primers (ERG11A, ERG11B) were used for PCR amplification and sequencing (Table 1 ). The 50 μl PCR reaction system contained 2.5 μl of 5× PrimeSTAR Buffer (Mg 2+ Plus), 4 μl of dNTP Mixture (2.5 mM each), 4 μl of 100 ng genomic DNA, 1 μl of 10 μmol/l of each primer and 0.5 μl of 2.5 U/μl PrimeSTAR HS DNA Polymerase (Takara, Dalian, China). PCR conditions were as follows: 35 cycles of 98
• C for 30 s; 98
• C for 10 s, 55
• C for 15 s and 72
• C for 60 s followed by 72
• C for 5 min. The PCR products were sent to the Beijing Genomics Institute (Shanghai, China) to be sequenced in both directions and compared to the published GenBank sequences for ERG11 (accession number XM711668).
Real-time PCR for gene expressions
RNAs of clinical isolates were extracted from YPD cultures in the mid-log exponential growth phase by using the Yeast RNAiso Kit (Takara, Tokyo, Japan). The PrimeScript RT reagent Kit with gDNA Eraser (Takara, Tokyo, Japan) was used to synthesize firststrand cDNA. Expression levels of 18S rRNA (250 times the dilution of the same genomic DNA) and those of the resistance genes ERG11, CDR1, CDR2 and MDR1 were assessed by realtime PCR using SYBR Premix Ex TaqTM II Kit (Tli RNaseH Plus) (Takara, Japan) in a 7900HTFast Real-time PCR System (Applied Biosystems, USA). All primers and cycling conditions were as described in previous study (Liu et al. 2015) . The mRNA expression levels of ERG11, CDR1, CDR2 and MDR1 gene for each isolate were compared with the average expression levels of 10 fluconazole susceptible isolates after normalization to an 18S rRNA control amplified at the same time with target genes. The mRNA expression level of each target gene with a measured Ct value below the 3.0 standard deviations range measured in susceptible isolates was considered significant overexpression (Chau et al. 2004 ).
Construction of strains by site-directed mutagenesis
The wild-type ERG11 gene sequences and double mutant sequences were amplified by PCR (PrimeSTAR HS DNA Polymerase; Takara) from Candida albicans Sc5314 or clinical isolate C1 (only containing T123H and Y132H substitutions) genomic DNA using the primers ORFKpnI and ORFXhoI. The products were then inserted into shuttle plasmid pYES2/CT with restriction digestion and ligation to create wild-type pYES2-ERG11 and mutant pYES2-TYH. The wild-type ERG11 gene sequences were used as templates for PCR amplification to introduce the C368T (T123H) point mutation and the T394C (Y132H) point mutation with special primers by ligation independent cloning by Exonuclease III method (Li and Evans 1997) . For C368T point mutation, the primers OverHindIII, T123Hfor, T123Hrev and OverEcoRI were used to create recombinant plasmid pYES2-T123H. The primers OverHindIII, Y132Hfor, Y132Hrev and OverEcoRI were used to introduce the T394C point mutation to create recombinant plasmid pYES2-Y132H, which was also selected as a resistance-positive control because of its significant increase in fluconazole resistance according to a similar study (Xiang et al. 2013) . All recombinant plasmids were transferred into E. coli strain DH5α cells with selection on LB agar plates containing 100 μg/ml ampicillin. Plasmid DNA was extracted and purified by plasmid extraction kit (Tiangen Biotech, Beijing, China). Recombinant plasmids were sequenced using the ERG11 sequencing primers to confirm the existence of each mutation.
Heterologous expression of CaErg11p in Saccharomyces cerevisiae
The recombinant plasmids pYES2-ERG11, pYES2-TYH, pYES2-T123H and pYES2-Y132H were transformed into competent S. cerevisiae INVSc-1 strains by chemical transformation method in selective SD-URA3-2% glucose agar plates. The INVSc-1 transformants were suspended in SD-URA media without any source of carbon for 5 h to allow the subject to consume glucose and then cultured in SD/Gal/Raf/-Ura media for 24 h to induce the expressions of the wild-type and mutant ERG11genes.
Azole susceptibility testing
The minimum inhibitory concentrations (MICs) of fluconazole, itraconazole and voriconazole for clinical isolates were obtained by using the broth microdilution method outlined in CLSI M27-A3 standard guideline document (2008). The MIC breakpoints for fluconazole, itraconazole and voriconazole were determined as follows: fluconazole-susceptible = ≤8 μg/ml, susceptible-dose dependent (SDD) = 16-32 μg/ml and resistant = ≥64 μg/ml; itraconazole-susceptible = ≤0.125 μg/ml, SDD = 0.25-0.5 μg/ml and resistant = ≥1 μg/ml; and voriconazole-susceptible = ≤1 μg/ml, SDD = 2 μg/ml and resistant = ≥ 4 μg/ml. And ATCC 90028 strain and ATCC 22019 strain were used as controls. Saccharomyces cerevisiae transformants were produced using a slightly modified procedure. RPMI1640 media were replaced with SD/Gal/Raf/-Ura media. The transformants after heterologous expression were suspended in sterile water until the optical density at 600 nm was 0.2. And then the working colony concentration was diluted 50 times and then another 20 times in SD/Gal/Raf/-Ura media. Then, 100 μl of SD/Gal/Raf/-Ura medium was used to inoculate a series of azole dilutions, with the maximum concentrations of fluconazole, itraconazole and voriconazole being 128, 32 and 32 μg/ml respectively. Then the media were incubated at 30
• C for 72 h.
We also spotted serial dilutions of INVSc-1 transformants cultures into SD/Gal/Raf/-Ura agar plates containing serial concentrations of azole that were performed as another susceptibility test. The transformants were pre-induced at 30
• C for 24 h in SD/Gal/Raf/-Ura medium and then diluted to 10 7 cells/ml in normal saline. Serial 10-fold dilutions were prepared and 5 μl of each dilution were spotted onto SD/Gal/Raf/-Ura agar plates with or without azole. The plates were incubated at 30
Homology modeling of CaErg11p
We modeled the homology of CaErg11p using a by I-TASSER server (http://zhanglab.ccmb.med.umich.edu/I-TASSER/) with crystal structure of lanosterol 14-α demethylase of S. cerevisiae with intact transmembrane domain bound to itraconazole (PDB code: 4K0F) as the template (Yang and Zhang 2015; .
RESULTS
Correlation of clinical isolates carrying T123I and Y132H substitutions in CaErg11p with azole resistance
We measured the MIC values of fluconazole, voriconazole and itraconazole in 27 fluconazole resistant isolates containing T123I and Y132H homozygous substitutions of CaErg11p. Results are shown in Supplementary S1, Supporting Information. Among the 27 isolates, 18 (67%), 26 (96%) and 18 (67%) isolates were resistant to fluconazole, itraconazolele and voriconazole, respectively, while 16 (59%) isolates were pan-azole-resistant. The mRNA expression levels of resistance genes including ERG11, CDR1, CDR2 and MDR1 were determined by qPCR and the results are shown in Supplementary S1, Supporting Information. For these isolates, there were significantly increasing expression levels of ERG11 gene than susceptible isolates (P < 0.05). However, overexpressions of CDR1 and CDR2 gene were not found in any of these isolates. Overexpression of MDR1 gene was detected in only three isolates, and there was no statistically significant difference of the expression of MDR1 gene between the 27 resistant isolates and susceptible isolates.
Assessment of azole susceptibility in Saccharomyces cerevisiae transformants expressing different versions of CaErg11p
We used site-directed mutagenesis to construct a series of plasmids expressing different versions of CaErg11p (wild-type version from Sc5314 genomic DNA, single substitution T123H or Y132H, or double substitutions). Each of the plasmids was transformed into the budding yeast S. cerevisiae and the resulting transformants were assayed for azole susceptibility, using the modified broth microdilution method and a spot assay. As shown in Table 2 , transformants were tested for their susceptibility to fluconazole, voriconazole and itraconazolele in the modified broth microdilution method. Transformants expressing either the substitution T123H or Y132H displayed higher (4-to 16-fold) MIC values to fluconazole and voriconazole than those expressing the wild-type version of CaErg11p, but this was not the case with itraconazolele. Unexpectedly, the MIC value could not be acquired in transformants expressing the double substitutions because these mutant cells showed extremely poor growth in micro broth. For this reason, we tested the azole susceptibility of the double-substitutionsexpressing S. cerevisiae transformants using a qualitative spot assay. Yeast cells expressing different versions of CaErg11p were inoculated on SD/Gal/Raf/-Ura agar plates supplemented with different concentrations of fluconazole and voriconazole (Fig. 1) . Although the slow-growth phenotype still exists, transformants expressing the double substitutions of CaErg11p exhibited a significant growth advantage over those expressing only a single substitution on plates with a concentration of voriconazole at 8 μg/ml, suggesting that the newly identified amino acid substitution T123I of the CaErg11p imposes a synergistic effect on the substitution Y132H in terms of voriconazole resistance.
Homology model of CaErg11p
We mapped the localization of residues Tyr132, Thr123, Y132H substitution and T123I substitution to the 3D model (Fig. 2) . The Y132H substitution is located at the heme-binding site, and the T123I substitution is near the active center and substrate access channel of the protein, supporting the observations that muta- tions of these sites may promote azole resistance by affecting the enzymatic activity of CaErg11p.
DISCUSSION
The amino acid substitution of CaErg11p is the most prevalent and important mechanism contributing to Candida albicans azole resistance (Ying et al. 2013) . Consistent with this notion, the results indicate that ERG11 mutations and overexpression may be responsible for the azole resistance of the 27 clinical isolates tested, which cannot be explained by transcriptional upregulation of drug efflux-encoding genes such as CDR1, CDR2 and MDR1. Genomic sequencing analysis identified a novel amino acid substitution, T123I, present in both alleles of the ERG11 gene in 27 azole-resistant clinical isolates that harbor a simultaneous substitution Y132H, which has been confirmed to confer azole resistance in previous studies (Sanglard et al. 1998; Xiang et al. 2013) . This newly identified amino acid substitution T123I is not 'silent' with respect to drug resistance. In contrast, the new substitution is present at high frequency in azole-resistant isolates and actively precipitates in driving the resistance to fluconazole and voriconazole. More importantly, these findings suggest that this substitution has a synergistic effect on a previously described substitution Y132H because the cells harboring double substitutions exhibited much stronger voriconazole resistance at 8 μg/ml than the individual substitution, even though the double substitutions cause a severe defect in vegetative growth. Here, we took advantage of the Saccharomyces cerevisiae heterologous gene expression system to evaluate the role of C. albicans ERG11 point mutations in azole resistance, which has been described previously (Sanglard et al. 1998; Kontoyiannis, Sagar and Hirschi 1999; Xiang et al. 2013) . We used a modified version of the CLSI broth microdilution method, and results showed that the amino acid substitution T123I alone contributed to a 4-fold increase in fluconazole and voriconazole MICs. Its resistance to voriconazole was significantly more pronounced than that of wild-type but less pronounced than those of the substitution Y132H. This was also confirmed by a quantitative spot assay. The substitution T123I was found to impose a synergistic effect on the substitution Y132H because transformants expressing both substitutions are able to tolerate an extremely high concentration of voriconazole (8 μg/ml), which are lethal to transformants expressing individual substitutions. Interestingly, results showed that heterologenous expression of a version of CaErg11p harboring both T123I and Y132H substitutions in S. cerevisiae produces defects in vegetative growth.
The ERG11 gene encodes a lanosterol 14-alpha-demethylase, an enzyme of the cytochrome P450 family for ergosterol biosynthesis in both S. cerevisiae and C. albicans (Lees et al. 1995; Lamb et al. 1999) . As shown in the structure model, Tyr132 is located on flexible BC loop of the enzyme and the heme-binding site, and Thr123 is located at the helix and close to the heme-propionate side chain of the enzyme. The active site of CaErg11p might be destroyed by T123I substitution and Y132H substitution. Nonfunctional proteins of CaErg11p may interfere with the normal function of ScErg11p of S. cerevisiae, and consequently, the defects of ergosterol synthesis hindered the growth of S. cerevisiae. The spot assay showed that the yeast cells harboring both CaErg11p substitutions grew exactly the same with or without drug treatment, indicating that the growth of yeast cells requires initiation at a certain concentration. In other words, these growth defects may be regulated by a quorum-sensing mechanism. Quorum sensing is a strategy of communication used by microbes in response to population density, and it is mediated by the release of signaling molecules (Albuquerque et al. 2013; Youk and Lim 2014) . In this way, non-functional proteins of CaErg11p might hinder the growth of S. cerevisiae by affecting the release of signaling molecules.
In conclusion, ERG11 mutations and overexpression are common and important mechanisms involved in azole resistance in clinical isolates of Candida albicans. Using a heterogeneous S. cerevisiae expression system, we validated the role of a novel functional CaErg11p substitution (T123I) in conferring resistance to fluconazole and voriconazole. We discovered a previously unreported synergistic effect between this substitution and the substitution Y132H in mediating the resistance to voriconazole. This work shows that targeting the azole resistance mechanisms driven by genomic changes of ERG11 may be an efficient preventative strategy for C. albicans infection.
